Ying-Yi Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying-Yi Hu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jun Zhang
Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, China
1 shared publication - Xi Song
Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, China
1 shared publication - Yi-Tao Zhou
Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, China
1 shared publication - Zi-Xin Tian
Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, China
1 shared publication - Zi-Xuan Wang
Institute of Molecular Medicine and Oncology, Chongqing Medical University, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (4) , 206-211
A Novel Pathogenic Haplotype in CDH23 Causing DFNB12: The Combined Effect of Two Individually Benign Variants
Background: Aberrations in cadherin-related 23 (CDH23) account for a significant proportion of familial autosomal recessive non-syndromic hearing loss (DFNB12), a common subtype of hereditary hearing loss worldwide. Aims: This study aimed to elucidate the molecular basis and pathogenic mechanism of DFNB12 in an affected girl from a nine-member pedigree. Study Design: Family-based genetic study with pedigree analysis. Methods: Clinical whole-exome sequencing combined with pedigree analysis was used to identify disease-causing mutations. The potential functional consequences of these mutations were investigated using structural bioinformatic approaches, including homology modeling, molecular dynamics simulations, and other relevant tools. Results: The proband carried compound heterozygous variants: a known pathogenic maternal variant (c.6049G > A) and a paternal haplotype comprising two linked variants (c.3262G > A and c.6911G > A), each individually classified as benign. Pedigree segregation analysis demonstrated that the paternal haplotype acts as a single pathogenic allele. Conclusion: Two individually benign variants can combine to form a novel pathogenic haplotype (c.3262A–c.6911A). This mechanism may be under-recognized in routine variant interpretation pipelines. Our findings underscore the importance of evaluating the combined effects of linked benign variants to ensure accurate genetic counseling.
- 1 April 2026
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 43 (4) , 206-211
Open AccessA Novel Pathogenic Haplotype in CDH23 Causing DFNB12: The Combined Effect of Two Individually Benign Variants
Background: Aberrations in cadherin-related 23 (CDH23) account for a significant proportion of familial autosomal recessive non-syndromic hearing loss (DFNB12), a common subtype of hereditary hearing loss worldwide. Aims: This study aimed to elucidate the molecular basis and pathogenic mechanism of DFNB12 in an affected girl from a nine-member pedigree. Study Design: Family-based genetic study with pedigree analysis. Methods: Clinical whole-exome sequencing combined with pedigree analysis was used to identify disease-causing mutations. The potential functional consequences of these mutations were investigated using structural bioinformatic approaches, including homology modeling, molecular dynamics simulations, and other relevant tools. Results: The proband carried compound heterozygous variants: a known pathogenic maternal variant (c.6049G > A) and a paternal haplotype comprising two linked variants (c.3262G > A and c.6911G > A), each individually classified as benign. Pedigree segregation analysis demonstrated that the paternal haplotype acts as a single pathogenic allele. Conclusion: Two individually benign variants can combine to form a novel pathogenic haplotype (c.3262A–c.6911A). This mechanism may be under-recognized in routine variant interpretation pipelines. Our findings underscore the importance of evaluating the combined effects of linked benign variants to ensure accurate genetic counseling.